Current best evidence on prescribed drugs

Pills
Drugdocs Logo

Current best evidence on prescribed drugs

Pills
HomeDrugsDRUGDOCS AIAboutNewsGlossaryContact
HomeDrugsAIAboutNewsGlossaryContact

DRUG ▾

ABCDEFGHIJKLMNOPQRSTUVWXYZ

DRUG

CLASS

AI

News

Conjugated estrogens/bazedoxifene

(Duavee®)

Conjugated estrogens/bazedoxifene

Drug updated on 12/11/2024

Dosage FormTablet (oral; 0.45 mg conjugated estrogens and 20 mg bazedoxifene)
Drug ClassConjugated estrogens and estrogen agonist/antagonists
Ongoing and
Completed Studies		ClinicalTrials.gov

Indication

  • Indicated in women with a uterus for the treatment of moderate to severe vasomotor symptoms associated with menopause
  • Indicated in women with a uterus for the prevention of postmenopausal osteoporosis.

Latest News

loading GIF

Summary
This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

  • This summary is based on the review of three systematic review(s)/meta-analysis(es). [1-3]
  • Fezolinetant 45 mg significantly reduced the frequency of moderate to severe vasomotor symptoms (VMS) compared to all evaluated non-hormonal therapies, and there were no significant differences in VMS frequency reduction between fezolinetant 45 mg and any of the 27 hormonal therapy regimens studied.
  • Bazedoxifene (BZA) 20 mg combined with conjugated estrogens (CE) significantly improved daily hot flushes, moderate/severe hot flushes, sleep disturbances, and total Menopause-Specific Quality of Life (MENQOL) compared to placebo, with BZA 20 mg/CE 0.625 mg being more effective than BZA 20 mg/CE 0.45 mg.
  • The studies included women during or after the menopausal transition, with an average age of 61.24 years and a duration of menopausal symptoms of 90.83 weeks, making the findings particularly relevant for postmenopausal women experiencing these symptoms.
  • Eszopiclone and oral combined hormone therapy had higher rates of adverse event-related discontinuation compared to placebo/control, indicating potential safety concerns associated with these treatments.
  • Dropout rates were comparable between the interventions and placebo/control, suggesting similar tolerability across treatment options.